Trial Profile
A safety and efficacy trial of vemurafenib in BRAF V600E metastatic melanoma patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Dec 2015
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 01 Dec 2015 New trial record